Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

Kura Oncology names veteran biopharma finance leader Jennifer Fulk as CFO as it builds out its commercial-stage precision oncology business.

Rhea-AI Summary

Kura Oncology (KURA) appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. She joins the senior leadership team and will report to President, Chief Executive Officer and Chairman Troy Wilson.

Fulk has more than 20 years of financial and operating leadership experience in biopharmaceuticals and high‑growth public companies. Her background includes over 15 years at Eli Lilly in roles spanning commercial finance, R&D, investor relations, treasury and global operations. She later served as CFO of Talkspace and Soleno Therapeutics, and COO/CFO of 120Water.

At Lilly, she was CFO of the U.S. Bio‑Medicines business with P&L responsibility for a $2.5 billion neuroscience and immunology franchise and provided financial leadership for an annual oncology R&D portfolio of approximately $1 billion.

Positive

• New CFO appointed with more than 20 years of financial and operating leadership experience
• Prior P&L oversight for a $2.5 billion U.S. neuroscience and immunology business at Eli Lilly
• Led oncology R&D finance for an annual portfolio of approximately $1 billion at Eli Lilly

Negative

• None.

Key Figures

Appointment effective date: September 8, 2026 Financial leadership experience: More than 20 years Business P&L responsibility: $2.5 billion +1 more

Appointment effective date

September 8, 2026

Jennifer Fulk appointed Chief Financial Officer

Financial leadership experience

More than 20 years

Biopharmaceuticals, public companies, and high-growth businesses

Business P&L responsibility

$2.5 billion

Lilly U.S. neuroscience and immunology business

Annual R&D portfolio

Approximately $1 billion

Lilly Global Oncology Finance

Key Terms

precision medicines, menin inhibitor, acute myeloid leukemia, farnesyl transferase inhibition, +1 more

5 terms

precision medicines medical

"a biopharmaceutical company focused on precision medicines for the treatment of cancer"

Precision medicines are treatments designed to work for specific groups of patients identified by genetic, biological, or lifestyle characteristics, rather than a one-size-fits-all drug. They matter to investors because these therapies can be more effective and command premium pricing in smaller, well-defined markets—offering higher potential returns if successful but also concentrated development and regulatory risk, like betting on a tailored suit that fits only certain people.

menin inhibitor medical

"the FDA-approved once-daily, oral menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

acute myeloid leukemia medical

"NPM1-mutated acute myeloid leukemia"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

farnesyl transferase inhibition medical

"advancements in menin inhibition and farnesyl transferase inhibition"

Blocking the enzyme farnesyl transferase, which normally attaches a small lipid “farnesyl” tag to certain proteins so they can stick to cell membranes and send growth signals. Think of it like preventing a postage stamp from being added so a letter can’t be delivered to the right address. As a drug mechanism, it matters to investors because clinical trial outcomes, safety data, and regulatory decisions about these inhibitors can materially affect the value of companies developing them.

small molecule drug candidates technical

"Kura’s pipeline of small molecule drug candidates"

Small molecule drug candidates are low‑molecular‑weight chemical compounds designed to bind to specific biological targets in the body and change how those targets work; they are typically made by chemical synthesis and often can be taken as pills or small injectables. For investors, they matter because their progress through research, testing and approval drives a drug developer’s potential future sales and value—think of them as prototype keys being tested to fit molecular locks, where success or failure changes a company’s prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – 

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leadership team and report to Troy Wilson, Ph.D., J.D., President, Chief Executive Officer and Chairman of the Board.

“We are delighted to welcome Jennifer to Kura as we enter our next phase of development as a commercial-stage company,” said Dr. Wilson. “Jennifer brings both an exceptional breadth of experience across commercial, finance, R&D portfolio management, investor relations, and global operations, and a strong track record as a public-company CFO. As we work to maximize the commercial potential of KOMZIFTI^®, broaden the opportunity for ziftomenib and advance darlifarnib, her strategic judgment and financial leadership will be invaluable to disciplined capital allocation, strong execution, and long-term value creation.”

Ms. Fulk brings more than 20 years of financial and operating leadership experience spanning biopharmaceuticals, public companies, and high-growth businesses. After more than 15 years at Eli Lilly and Company, she served in a series of senior finance and operating leadership roles, including as Chief Financial Officer of publicly traded Talkspace, Chief Operating Officer and Chief Financial Officer of 120Water, and, most recently, Chief Financial Officer of Soleno Therapeutics.

During her tenure at Lilly, Ms. Fulk held increasingly senior roles spanning commercial finance, research and development, investor relations, treasury, and global operations. Her positions included Chief Financial Officer of Lilly’s U.S. Bio-Medicines business, with P&L responsibility for a $2.5 billion U.S. neuroscience and immunology business; Vice President, Investor Relations; and Executive Director, Lilly Global Oncology Finance, where she provided financial leadership for an annual R&D portfolio of approximately $1 billion.

“Kura has established a strong commercial foundation with KOMZIFTI and is advancing two differentiated precision-oncology franchises with significant potential,” said Ms. Fulk. “I am excited to join Troy and the Kura team at this important stage of the company’s evolution. I look forward to helping Kura build on its commercial momentum, allocate capital to its highest-value opportunities and execute with discipline across the business.”

Ms. Fulk holds a Bachelor of Science in Information Systems and a Master of Business Administration from Indiana University.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected contributions of Ms. Fulk as Chief Financial Officer; Kura’s plans to maximize the commercial potential of KOMZIFTI, broaden the opportunity for ziftomenib and advance darlifarnib; the potential of Kura’s two differentiated precision-oncology franchises; Kura’s capital allocation strategy and plans for disciplined execution across the business; and Kura’s ability to generate long-term value. Factors that may cause actual results to differ materially include the risk that the expected contributions of Ms. Fulk may not be as expected; the risk that Kura’s actual future financial and operating results may differ from its expectations or goals; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kura Oncology contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When does Jennifer Fulk’s appointment as Kura Oncology’s Chief Financial Officer take effect?

Jennifer Fulk’s appointment as Chief Financial Officer is effective September 8, 2026.

To whom will Jennifer Fulk report in her new role at Kura Oncology?

Jennifer Fulk will report to Troy Wilson, who serves as President, Chief Executive Officer and Chairman of the Board.

What previous senior roles has Jennifer Fulk held before joining Kura Oncology?

Jennifer Fulk previously served as Chief Financial Officer of Talkspace, Chief Operating Officer and Chief Financial Officer of 120Water, and most recently as Chief Financial Officer of Soleno Therapeutics. At Eli Lilly, she held senior roles including CFO of the U.S. Bio‑Medicines business, Vice President, Investor Relations, and Executive Director, Lilly Global Oncology Finance.

What are Kura Oncology’s current commercial and pipeline priorities mentioned in connection with the CFO appointment?

Kura is commercializing KOMZIFTI (ziftomenib), an FDA‑approved once‑daily oral menin inhibitor for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia. The company highlighted efforts to maximize KOMZIFTI’s commercial potential, broaden the opportunity for ziftomenib, and advance darlifarnib as part of its precision oncology franchises.